Treatment of CMV Enteritis

Initial Treatment Approach

The American College of Physicians recommends initiating intravenous ganciclovir 5 mg/kg twice daily immediately for 3-5 days, then transitioning to oral valganciclovir 900 mg twice daily to complete a total treatment duration of 21-28 days or until complete symptom resolution, particularly in immunocompromised patients where CMV enteritis represents serious mucosal disease requiring aggressive systemic treatment similar to CMV esophagitis 1, 2, 3
The Infectious Diseases Society of America suggests starting with IV ganciclovir for rapid therapeutic drug levels, ensuring adequate drug delivery during the critical initial phase when gastrointestinal absorption may be compromised by mucosal inflammation 1, 2, 3

The Centers for Disease Control and Prevention recommends initiating or optimizing antiretroviral therapy concurrently with CMV treatment in HIV-infected patients, and continuing CMV therapy until immune recovery occurs, defined as CD4+ count >100 cells/µL sustained for 3-6 months 3, 4
The American Society of Transplantation suggests reducing immunosuppression if clinically feasible while treating CMV enteritis in transplant and other immunosuppressed patients, and monitoring CMV viral load weekly by PCR to assess treatment response 3

The American College of Physicians recommends foscarnet 90 mg/kg twice daily as the primary alternative for patients with ganciclovir intolerance or resistance, requiring strict monitoring of renal function and electrolytes due to significant nephrotoxicity risk 2, 3
The Infectious Diseases Society of America suggests considering cidofovir as third-line therapy, but notes it carries substantial nephrotoxicity risk and should be reserved for refractory cases 2, 4

The Centers for Disease Control and Prevention recommends monitoring complete blood count, serum creatinine and electrolytes, and clinical symptom assessment twice weekly during the induction phase (first 3-5 days) 1, 3
The American Society of Transplantation suggests monitoring complete blood count, renal function, CMV viral load by PCR, and clinical response weekly during the maintenance phase 1, 2, 3

The American College of Physicians recommends tissue biopsy with histopathology showing characteristic CMV intranuclear and intracytoplasmic inclusions as the gold standard for diagnosis, as positive CMV culture alone is insufficient 2, 3

The Infectious Diseases Society of America notes that ganciclovir/valganciclovir commonly causes myelosuppression (neutropenia, anemia, thrombocytopenia), renal dysfunction, and that dose reduction or interruption may be necessary in up to 40% of patients due to hematologic toxicity 1, 3

The American College of Physicians recommends combination therapy with ganciclovir and foscarnet for sight-threatening CMV retinitis occurring concurrently with enteritis, but notes that for isolated gastrointestinal disease, monotherapy with ganciclovir/valganciclovir is standard 1, 4